Articles On Noxopharm (ASX:NOX)

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

Optiscan strives for ‘live biopsies’ for head and neck cancers LTR Pharma wins ethics clearance for fresh erectile dysfunction trial Noxopharm’s quest to cure lupus inches a step further Optiscan (ASX:OIL) will launch an imaging study of...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

After a strategy revamp, Noxopharm is targeting inflammatory diseases – lupus in particular Affecting five million people, lupus has proved a tricky disease to tackle The company is pondering a phase II trial, most likely in skin lupus No...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

ASX rises 0.22pc after flat day of trade Earnings reports from big cap companies weighed heavy Gains and losses equalised after lunch for steady end to day ASX edges higher on earnings equilibrium It was another tale of heroes and villai...

Ansell says it has reacted swiftly to new tariff imposts by raising prices in June, with more increases to come LTR Pharma reports satisfaction clean sweep in an erectile dysfunction trial Argent does the ARD yards with US in vivo trial R...

 Advances on research and development tax incentives are proving a popular source of ancillary financing Audeara shares surge up to 36% on China deal Bell Potter halves its Syntara valuation   With traditional equity fundraising conditio...

Noxopharm (ASX: NOX) has successfully completed the second dosing cohort in its first-in-human HERACLES trial for novel autoimmune drug candidate SOF-SKN. The safety steering committee confirmed the dose level was safe and tolerable, enabli...

ASX slips just 12.3 points, remaining near all-time high Healthcare leads losses as Trump raises tariff spectre Gains in gold and consumer discretionary soften losses   Profit takers stay their hands When markets hit new closing highs, it...

Gold stocks drive gains with index climbing 3.3pc ASX hits new record close at 8843 points Broad market strength with 10 of 11 sectors up Solid gains supported by gold It was another picturesque day of trading on the ASX today, rising st...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Australia’s S&P/ASX 200 rose 2.36% in July, posting gains of almost 9% so far for CY25 Health care had a dose of good medicine, rebounding 9% to be best performing sector for month Santa Fe Minerals jumps 739% in July after executing d...

Copper prices crash 20pc Materials sector undercuts market, down 2.57pc Info tech rally not enough to push ASX into positive territory   Tech rally fails to lift resources The ASX staged a steady recovery through the day to finish down ju...

Energy stocks climb as oil ticks up 2pc ASX rallies late to climb 0.08pc Gold stocks slide despite recovering gold price   ASX lifts as clouds part for energy sector The ASX was in a decidedly bad mood today, hanging out in negative terri...

A trade deal between the EU and US has staved off the worst tariff fears Telecoms led gains alongside financials and healthcare Banking stocks end bearish run, gaining 0.81pc   ASX holds its nerve After a shaky start to trade this morning...

ASX beats hasty retreat from new record high, down 0.79pc Info tech rises against the tide, adding 0.85pc Banks and financial stocks struggle alongside materials sector, leading losses Info tech fires up despite dour market The ASX unwoun...

Lumos Diagnostics says its US distribution deal is worth up to $487 million Impedimed’s US device sales are on a roll Noxopharm treats its first lupus trial patient   In one of the “largest distribution deals of its type” by an ASX-listed...

Noxopharm Ltd (ASX:NOX) has got its HERACLES trials out the gates in Week 29, dosing a preliminary patient in the first-in-human use of its SOF-SKN topical drug candidate targeting TLR7/8 for autoimmune diseases. Listen to the HotCopper...

EchoSolv enters Mayo’s gauntlet for FDA nod Echo’s AI flags heart failure before it hits the fan Other ASX stocks that have trialled with Mayo   On July 1, Echo IQ released an announcement that made cardiologists sit a little straighter....

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Nyrada is focused on a particular ion pathway to tackle disorders including stroke and traumatic brain injury Preclinical work has shown a significant reduction in secondary brain injury and cardiac damage CEO James Bonnar spent 15 years a...

Clarity is poised to launch its second phase III prostate cancer imaging trial LTR Pharma shares swell 30% on the back of local chemist deal   Trajan shares measure up at 70% above their current value   In launching its second phase III t...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Life science companies are turning to federal research & development tax refund advances to stave off capital raisings on unfavourable terms Biotechs undergoing eligible R&D know they will receive a federal R&D rebate, but ther...

Global drug companies again are on the alert after Donald Trump reiterated his intention to impose a pharma tariff rumoured to be 25% No sweat! as Botanix raises $40 million in a placement Imricor’s ablation news lauded as a “truly groundb...

Profit-making ASX biotechs have been caught up in the market rout During Brain Health Week, let’s not forget about dementia risks Argent looks for Malta site deal While few stocks or sectors have escaped the market correction – or almost...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Highlights: ASX 200 sees minor shifts, with inflation affecting broader market trends. Energy and Industrials show resilience, providing stability in uncertain conditions. Centaurus Metals and other ASX-listed companies stand out, sho...

A number of ASX-listed healthcare companies, many with relatively low market caps, are making strides in tackling cancer Imagion is  aiming to revolutionise cancer diagnosis by introducing molecular imaging to magnetic resonance imaging (M...

Noxopharm (ASX:NOX) has reported its lupus medication in development, SOF-SKN, has passed first-stage in vitro safety tests before clinical trials. The stock jumped 11% out the gate, to 10cps, on thin trades on Tuesday. Lupus is an au...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

Sonic reaffirms earnings guidance and says it is on the hunt for “sensible” acquisitions Boards face their inquisitors in peak AGM week Resonance shares soar on Sun Pharma deal   Pathology and radiology giant Sonic Healthcare (ASX:SHL) sa...

ASX rises, but MinRes drops over transparency issues Fed boss Powell’s cautious rate cut stance cools market optimism NoviqTech shares surge after securing blockchain funding   The ASX rose by 0.74% on Friday, with 10 out of 11 sectors fi...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Aussie shares slip as RBA holds rates steady MinRes rebounds, Domino’s Don Meij quits Investors rethink Trump comeback as Harris leads in Iowa   Aussie shares slipped into the red on Tuesday, falling 0.4% as sentiment remained subdued aft...

Highlights Tech stocks drive markets higher, with notable movements from Apple and Nvidia. European automobile stocks lifted on improved forecasts, while banking stocks saw slight declines. Commodities, including oil and metals, felt...

Control Bionics says it has overcome the “challenges” of the 2023-24 year Ord Minnett identifies the health sector stunners Noxopharm finds a drug manufacturer to kick-start its lupus trial   Health Check is renowned biotech journo Tim Bo...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX down as RBA holds rates steady again Element 25 lands US$166m grant talks Supermarket stocks drop again amid discount claims backlash   The ASX was down 0.3% at one point but rallied to a flattish close after the Reserve Bank kept in...

ASX up on Thursday, tech stocks rise boosted by NextDC Wodside Energy drops due to downgrade and oil price fall Iron Ore and coal slide, and Coronado sinks on production and cost issues   After a rough session on Wednesday, the ASX saw a...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

The ASX200 closed fairly flat at 8,103 points. Tomorrow sees the release of crucial Q2 growth numbers and analysts will slice and dice the data in an effort to predict the RBA’s next interest rate move. The Staples sector was aggressi...

Today’s Closing Bell is brought to you by WeBull Securities   ASX dipped as Woolworths and mining stocks fell Australia’s current account deficit widened Blackstone acquired AirTrunk’s data centres for $23.5 billion   The ASX dipped 0.08...

Noxopharm says two novel drug candidates significantly reduced glioblastoma (brain cancer) cell growth in preclinical models. Percheron Therapeutics announces “very encouraging” new data for its epilepsy program Cyclopharm is off to a soli...

Noxopharm (ASX: NOX) has made ‘substantial progress’ with its Chroma technology platform, reporting encouraging brain cancer results and early work on leukaemia. The Chroma drug development program focuses on generating first-in-class novel...

  Golden Deeps (ASX:GED) has announced that thick copper and zinc sulphide mineralisation has been intersected in diamond drilling of key targets at the Company’s Havilah Project. The results up to 18.5% Copper & 34.8% Zinc in initial p...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...